Committee Insights | 7.13.23 | Know Your Hazards – Occupational Health and Safety Considerations in Cannabinoid Ingredient Manufacturing

[embedded content]

Our multi-part series on minor, novel & synthetic cannabinoids concludes on Wednesday, July 26th at 1PM ET with Part V examining different approaches to regulating consumer products containing cannabinoids across the US and varied perspectives from cannabinoid product manufacturers on the impact these varying regulations have on their business — Register Now: https://bit.ly/3rFRj4g

—

NCIA’s #IndustryEssentials webinar series is our premier digital educational platform featuring a variety of interactive programs allowing us to provide you timely, engaging and essential education when you need it most.

In this edition of our NCIA Committee Insights series, originally aired on July 13, we were joined by members of NCIA’s Cannabis Manufacturing, Scientific Advisory and Hemp Committees for an in-depth discussion highlighting the occupational health and safety considerations to make during the manufacture of cannabinoids and provide recommendations for mitigating risk.

There is no mistaking that manufacturing cannabinoids is here to stay. It is more and more prevalent to see historically plant/naturally derived bulk ingredients being manufactured in a controlled environment in the lab or through innovative processes like precision fermentation. It is likely that bulk ingredient manufacturing of cannabinoids will go this route too.

For cannabinoids like HHC, that do not exist naturally in the plant or in high enough quantities to be commercially viable for extraction, it is most certainly the case that manufacture of these compounds will occur in the lab. To produce these compounds safely, we can luckily look toward existing regulations and occupational health and safety guidelines for producing novel ingredients for use in foods and non-foods.

Learning Objectives:

• Recognizing common occupational safety hazards associated with manufacturing cannabinoids and recommendation to mitigate these hazards

• Learning the different occupational safety considerations between isolation and purification of naturally occurring cannabinoids and the manufacture (synthesis) of cannabinoids in the lab

• Understanding the special safety considerations that processes like hydrogenation and others have and why these are critical to mitigating liability for your business

Panelists:

Jacob Enslein
Consultant
AJ Cannabis Consulting

Rhiannon Woo
Co-Founder & CSO
TraceTrust

Tenay Woodard
Director of Safety & Security
KIVA Brands, Inc.

Tucker Holland
Co-founder, CFO and Processing Director
Entourage Cannabis

Keith Butler
CEO
OP Innovates / Naturia+™

—

This is fourth in a multi-part series of #IndustryEssentials webinars. You can watch Parts I, II & III at the links below.

Defining the Conversation: Minor, Novel & Synthetic Cannabinoids (Part I): https://bit.ly/3D2LReB

Meet the Minors (Part II): https://bit.ly/3qUD8Ip

From Lab to Label: Safeguarding Consumers in the Cannabinoid Product Landscape (Part III): https://bit.ly/3Xc9Lx6